Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Leading Innovations and Remedial Insights into the Parkinson's Disease
- Parkinsons Disease 2018

About

ALLIED ACADEMIES every year hosts interdisciplinary international conferences worldwide on cutting-edge basic and applied research in life sciences, Pharma, medicine, healthcare and nursing delivered by the best talents in industry and academia. Our conferences are oriented to drive the scientific community at large, facilitating access to the newest technical and scientific achievements and to shape future research directions through the publication of applied and theoretical research findings of the highest quality.


We take the honor to welcome all the Healthcare professionals, company’s, research centers and laboratories belonging to the field of Neuroscience and Neurodegenerative disorders towards the 10th World Congress on Parkinson's Disease and Movement Disorders during May 25-26, 2018 at New York, USA.

Welcome Message

Allied Academies is pleased to welcome all the Deans, Heads, Practitioners, researchers, scientists, professors and young researchers who are contributing towards the field of Neurology and Neuroscience for "10th World Congress onParkinson's Disease and Movement Disorders during May 25-26, 2018 at New York, USA". The theme of Parkinsons Disease 2018 conference is based on "Leading Innovation and Remedial Insight of Parkinson’s Disease". The Conference will serve as an informative and unique podium providing researchers and the healthcare concerns, to share, discuss, learn exchange and initiate the betterment In the Neurological World.

Parkinson’s disease is one of the most common neurodegenerative disorders. It is estimated to affect up to 160 per 100,000 of the general population with an annual incidence of 15–20 per 100,000. Many population studies have shown the rising prevalence with age (up to 2% of the population aged 80 and over). Around 1 in 7 cases are diagnosed below the age of 60 years. The costs of treatment have been estimated at between £560,000 and £1.6 million per 100,000 of the population.

In USA a 3-year prospective study of the economic cost of PD was performed in 2006. The average annual cost per patient was estimated at $12,091, out of which 55.9% accounted for direct costs. Drugs took up the major share of direct costs, $5,763 per year. Indirect costs accounted for $4,851 per patient per year. Within this, 76% of the costs were related to nursing care and the loss of productivity.


Why to attend???

Conduct demonstrations, workshops, and symposiums, distribute information, meet with current and potential national & international experts, make a splash with a new product line, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Neurodegenerative fields are hallmarks of this conference.

It is our greatest pleasure to welcome you to the 10th World Congress on Parkinson’s Disease and Movement Disorders (Parkinsons Disease 2018), that aims at bringing together the professors, physician researchers, surgeons, health educators, nurse researchers and students in all areas of Parkinsons Disease and to provide an international forum for the dissemination of original research results, new ideas, innovations and practical development experiences which concentrate on both theory and practices. Our aim is to aggregate researchers, academicians and scientists from the Parkinson community and to create an avenue towards robust exchange of information on latest technological advances, new scientific achievements, and the effectiveness of various regulatory programs towards Parkinson's disease.

Target Audience

Directors, Neurologist, Neurosurgeons, Psychiatrist, Surgeon, Head of department, Industries, Business delegates, Clinicians, Community Members, Professors and Students from Academia in the research of Parkinson's Disease and Movement Disorders.



Sessions

Parkinson's disease is the second most common neurological disorder. The number of new cases per year of PD is between 8 and 18 per 100,000 person–years. There are about 7 Million people affected with PD globally and about 1 Million of them belong to the United States Only. According to various study and case reports the onset of the Parkinson's or movement disorders range from the age of 50 and above. However, in some cases the tremor is experienced early and considered as young onset PD. Many studies and theories have been carried, considering the risk factors and the protective measures for the onset of the PD, though the results were flawed and predictable.

 

Session on: Epidemiology of Parkinson’s disease

Parkinson’s is one in every of the well-known age connected neurodegenerative disorder, second in return simply to Alzheimer's disease. Parkinson’s disease conjointly causes intensive injury of the motor or sensory pathways extending on the far side the pigmental brain stem nuclei.  There are nearly seven Million individuals affected with Parkinson globally and nearly one Million of them belong to the US solely. In line with varied study and case reports the onset of the Parkinson’s or movement disorders vary from the age of fifty and above. However, in some cases the tremor is intimate with early and thought of as young onset Parkinson’s. Several studies and theories are carried, considering the danger factors and also the protecting measures for the onset of the Parkinson, though the results were imperfect and foreseeable. 


Session on: Risk factors of Parkinson's disease

Risk factor for the Parkinson’sdisease chiefly depends on age, hereditary, sex and exposure to toxins. The causes of the disease are believed to be either genetic or environmental. Parkinson is commonest in men than women. Advancing age could be an issue that's more systematically related to an increase in the Parkinson’s disease; nearly 5%-10% of individuals get Parkinson's disease before the age of forty. It involves a number of the symptoms like anxiety, psychological feature issues, tremor or shaking, depression, hassle sleeping, low voice, loss of smell etc. Now a day’s Head injury and Gene variation is additionally an element for Parkinson’s disease.


Session on: Diagnosis of Parkinson's disease

The identification of  Parkinson’s disease is incredibly troublesome in its earlier stages, it goes unnoted or the result is not obtained. There is no direct treatment for Parkinson’s disease and also there is no biopsy or brain scan that confirms the diagnosis. Treatment is completely based on the medical record and a neurologic examination. At present there's no cure for Parkinson, medications will reduce its symptoms and later stages surgery may be done. Medications are in 3 stages- initial stage includes the drug known as levodopa that increase the monoamine neurotransmitter in the brain, the second set of medicine eases a number of the Parkinson’s disease symptoms and also the third set of medicine helps to manage the non-motor symptoms as well as depression.


Session on: Complications of Parkinson's disease

Parkinson's disease is not thought to be a life threatening condition; however it has a massive impact of your personal satisfaction. With time, the illness will bring forth problems with speech, movement, and brain functioning. The foremost common complication in Parkinson’s disease are Thinking difficulties, Depression and blood pressure changes, emotional changes, Swallowing issues, Sleep issues and sleep disorders, Bladder issues, Constipation, Smell dysfunction, Fatigue, Pain, Sexual dysfunction and gut and Bladder Complications.  Parkinson is not fatal; however it will cut back longevity. The disease progresses quickly in older patients, and will cause severe incapacity within ten - twenty years.


Session on: Vasculogenesis and Angiogenesis

Angiogenesis has not been extensively studied in Parkinson's disease despite being related to different neurodegenerative disorders. Angiogenesis, i.e., the formation of blood vessels, has been connected to Parkinson’sdisease pathogenesis —post mortem analysis of patient’s brains has known inflated numbers of nuclei from endothelial cells, blood vessels and enlarged levels of specific angiogenesis biomarkers. However angiogenesis’ role in Parkinson’s disease is not nonetheless fully established and understood. Angiogenesis in the brain is going to be the reason behind balance difficulties and intractable walking for those who suffer from Parkinson’s disease.


Session on: Navigating life with Parkinson's disease

Managing the routine chores and living with Parkinson’s becomes a priority because the incapability and loss of coordination might trigger the people into depression or lower their self-esteem. It is vital to develop a solid Parkinson’s disease management set up as Parkinson’s disease is a chronic disease. Managing with Parkinson includes building a health care team with proper doctors, proper intake of medicines, exercises, nutrition and sleep.


Session on: Pathophysiology of Parkinson's disease

Parkinson’s disease is primarily associated with the gradual loss of cells inside the bodily structure of the brain. This area is responsible for the assembly of monoamine neurotransmitter. Monoamine neurotransmitter is a chemical messenger that transmits signals between two regions of the brain to coordinate activity. For instance, it connects the bodily structure and conjointly the striatum to manage muscle activity. If there is deficiency of Dopastat at intervals the striatum the nerve cells throughout this region “fire” out of management. This leaves the individual unable to direct or control movements. This lands up in the initial symptoms of Parkinson. since the disease progresses, various areas of the brain and nervous system degenerate to boot inflicting a lots of profound movement disorder.


Session on: Leukodystrophy

Leukodystrophy isn’t only one disease; it’s really a group of diseases that have an effect on the central nervous system. Doctors are discovering new types of leukodystrophy all the time, however consultants presently apprehend of about fifty two completely different types. Most of the leukodystrophies are genetic. Typically symptoms can show up early in childhood.  Since the diseases are progressive, that means they deteriorate over time, some youngsters born with a sort of leukodystrophy could seem fine. Children with leukodystrophy can have the following problems: Balance and mobility problems, Behavioral and learning disabilities, Bladder issues, Breathing difficulties, Developmental delays, Hearing, speech, and vision problems, Muscle control disorders, Seizures.


Session on: Dystonia

Uncontrollable muscle contraction which results in movement disorder in individuals is termed as dystonia.  The body parts twist involuntarily which results in repetitive movements or abnormal postures. One muscle, a muscle group, or the entire body may get affected due to dystonia. About 1% of the population gets affected by dystonia, and in which women are more affected than men. A "dragging leg", Cramping of the foot, Involuntary pulling of the neck, Uncontrollable blinking, and Speech difficulties are few symptoms of dystonia. There is no specific cause for dystonia. Depending upon the body part it affects dystonia is classified into many types such as generalized dystonia, Focal dystonia, multifocal dystonia, Segmental dystonia, Hemi dystonia.


Session on: Mitochondrial dysfunction

A characteristic of aging, and essentially, of all chronic diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis is mitochondrial dysfunction, which is characterized by a less efficiency in the electron transport chain and reductions in the synthesis of high-energy molecules, such as adenosine-5-triphosphate. Mitochondrial dysfunction acts causally in disease pathogenesis and occurs early in all age-related chronic diseases. Disease-specific proteins interact with mitochondria in an impressive number. Mitochondrial dysfunction is linked to Parkinson’s disease through the evidences provided by the induction of Parkinson by neurotoxins that inhibit mitochondrial complex I.


Session on: Bradykinesia

Reduced pace in bodily movements of a person is generally termed as BradykinesiaParkinson has four key symptoms and Bradykinesia is one among them. Stroke, Schizophrenia, HyperammonemiaProgressive supranuclear palsy are few connections of Bradykinesia. According to studies more men are affected by Bradykinesia than women. 


Session on:  Cell vulnerability and progression

The primary objectives of basic and clinical research in Parkinson’s disease are the understanding of the different vulnerability of the dopaminergic neurons from midbrain regions and the mechanisms whereby pathology becomes widespread. To progress in stopping neurodegeneration in Parkinson’s disease it is mandatory to understand the mechanism responsible for intrinsic SNc neuronal vulnerability. The disease progresses in three different stages: Early, Moderate and Advanced stages. In the early stage tremor is the first symptom. As the disease progresses it may lead to Dementia in few cases. 


Session on: Biomarkers in research

Biomarkers are desperately required for the identification and observation of disease progression in Parkinson’s disease. A trait biomarker indicates susceptibility to a disease, a state biomarker is diagnostic of a disease, and a rate biomarker tracks progression of the disease. A biomarker can be clinical, imaging-based, genetic, or biochemical. Various biologic specimens are potential candidates for identifying biochemical biomarkers; these include cerebrospinal fluid, blood components, urine, and skin. These are mostly because of variation within the macromolecule species detected by totally different antibodies, restricted numbers of patients in some studies, or inadequate control of many vital variables. The event of biomarkers for Parkinson’s disease would have tremendous utility. It may prove to be helpful in early diagnosis and in identifying subgroups of Parkinson.


Session on: Therapeutics for Parkinson's disease

The subsequent introduction of levodopa and the demonstration that dopamine loss is the key pathological feature of Parkinson's disease (PD) have revolutionized the field of Parkinson’s disease therapeutics. Nearly 15 percent of people with Parkinson’s disease have motor symptoms that are not well-controlled with levodopa. Another potential therapy for Parkinson’s disease is transplantation of dopaminergic tissue. A group of drugs that act directly on dopaminergic receptors called Dopamine agonists are used as adjuncts to levodopa in the treatment of Parkinson’s disease.


Session on: Neuroprotective treatments

Advances in understanding the molecular mechanisms of necrobiosis and therefore the pathologic process of intermittent and familial Parkinson's disease are making new opportunities for the development of Neuroprotective and/or neurorestorative therapies. Current therapies for Parkinson’s disease ameliorate symptoms within the early phases of disease however become less effective over time, as the underlying disease progresses. Therapies that slow the progression of Parkinson’s disease are required. However, there are comparatively few clinical trials aimed toward demonstrating neuroprotection. Many potential Neuroprotective compounds, representing a wide range of mechanisms, are out there and benefit further investigation in Parkinson’s disease.


Session on: Neurotransmitter -Dopaminergic drugs

The dopaminergic drugs acts as neurotransmitters in Parkinson’s disease. In the brain these dopaminergic drugs or actions increase the dopamine-related activity.  Proteins, enzymes that regulate the biosynthesis or metabolism of dopamine and neurons that synthesize dopamine can also be classified as dopaminergic.

Market Analysis


Organizing Committee
OCM Member
Dr. A. Q. Rana
Director, Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre
Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre
Toronto, Canada
OCM Member
Omar El-Agnaf
Director of Neurological Disorders Center (QBRI) and Professor at Hamid Bin Khalifa University (HBKU)
Hamad Bin Khalifa University (HBKU)
Al Luqta St, Qatar
OCM Member
Prof. Dr. Cynthia Bedeschi
Doctor and Master in Neuroscience and Behavior - USP Specialist in Physiotherapy in Neurology - USP
Universidade Paulista - UNIP
Sao Paulo, Brazil

To Collaborate Scientific Professionals around the World

Conference Date May 25-26, 2018
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Venue
&
Hospitality

Hilda Cangelosi ~ Director of Sales

Hilton New York JFK Airport Hotel

144-02 135th Avenue | Jamaica, New York 11436 | USA

Tel +1 718-269-3028

Fax +1 718-269-2691

Join The Discussion

Mail us at

Drop us a mail for program enquiry
parkinsons@alliedconferences.org
Sponser/Exhibiting/advertising
parkinsonsdisease@alliedmeetings.com
General queries
parkinsons@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com
Copyright © 2017-2018 Allied Academies, All Rights Reserved.